Medicortex has launched a crowdfunding campaign in order to generate support for developing a diagnostic kit for brain injury detection. The target is 200,000 Euro with a maximum of 560,000 Euro offering equity of between 4.76 and 12.28 percent. The price per share is 4 Euro with a minimum investment of 125 shares. The campaign runs until May 10, 2017. https://www.invesdor.com/en/pitches/787?utm_source=client&utm_medium=email Medicortex was founded in 2014 by Dr. Adrian Harel a veteran of the Israei biotech industry. The company is developing a rapid diagnostic test for detection of traumatic brain injury (TBI) and concussion. TBI is caused by a hit to the head or a sudden motion of the head. The incidence rate of head injury is increasing. For example, in the US the annual average of documented injuries was approximately 1.7 million between years 2001 – 2007, but it grew to 2.5 million cases by 2010. It is estimated that about 2 % of people are continuously living with and suffering from chronic sequelae of TBI. It is called a silent epidemic because of relatively high prevalence and the general unawareness associated with the condition. In sports, an undiagnosed case of TBI can result in premature return-to-play with severe consequences, or in an early onset of chronic neurodegenerative conditions. TBI and concussion are severely underdiagnosed conditions. The company’s vision and motivator is the chance to offer a solution for the common human problem and help the individuals who have suffered TBI to be better aware of the condition and manage the situation. Once the development of the diagnostic kit is complete, the next goal is to expand the program to the development of innovative drug to halt the progression of brain injury.